Victory Capital Management Inc. trimmed its position in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 5.2% in the third quarter, Holdings Channel reports. The institutional investor owned 134,480 shares of the company’s stock after selling 7,390 shares during the period. Victory Capital Management Inc.’s holdings in Kiniksa Pharmaceuticals were worth $3,429,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of KNSA. Hillhouse Capital Management Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals in the second quarter worth $99,529,000. Baker BROS. Advisors LP bought a new position in Kiniksa Pharmaceuticals during the second quarter worth $52,050,000. Boxer Capital LLC bought a new position in Kiniksa Pharmaceuticals during the second quarter worth $20,346,000. FMR LLC bought a new position in Kiniksa Pharmaceuticals during the second quarter worth $14,565,000. Finally, VHCP Management II LLC bought a new position in Kiniksa Pharmaceuticals during the second quarter worth $11,091,000. Institutional investors and hedge funds own 36.44% of the company’s stock.
KNSA has been the topic of a number of research reports. JMP Securities boosted their target price on shares of Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the stock an “outperform” rating in a research report on Monday, September 17th. Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, September 11th. Finally, Zacks Investment Research lowered shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Kiniksa Pharmaceuticals has an average rating of “Buy” and an average price target of $31.75.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Thursday, November 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.03. Research analysts forecast that Kiniksa Pharmaceuticals Ltd will post -2.63 earnings per share for the current year.
Kiniksa Pharmaceuticals Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Read More: What Is An Exchange-Traded Fund (ETF)?
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA).
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.